IndustryCompany release

Verrica reports record Q3 YCANTH sales of $5.7M as first common warts Phase 3 enrolment completes

🇺🇸 Verrica Pharmaceuticals Inc. (VRCA) · Thu 12 Nov 2026

The dermatology company's U.S. YCANTH revenue rose 57.9% year over year, while enrolment in the first of two pivotal common warts trials is finished.

Verrica Pharmaceuticals reported third-quarter 2026 results on 12 November, citing U.S. net product revenue for YCANTH of $5.7M, up 57.9% on the same period a year earlier. Total revenue for the quarter was $6.9M.

On the pipeline side, the company said enrolment is complete in the first of two pivotal Phase 3 trials of YCANTH in common warts. Topline data from that first trial are expected in the first quarter of 2027, with the second trial due to report in mid-2027.

Verrica also said it has unlocked the remaining $15.0M of its $27.5M credit facility. In addition, the company is exploring VP-315 for Gorlin syndrome.

The available information does not include further detail on trial design, endpoints, the funding terms or the Gorlin syndrome plans, so those points remain to be clarified in the company's full results documents.

What it means for your team

  • Market-access teams can track YCANTH's U.S. uptake: the 57.9% year-on-year rise in net product revenue gives a current commercial data point.
  • A common warts indication would be a potential label expansion for YCANTH, with topline readouts expected in Q1 2027 and mid-2027; regulatory teams should watch for any subsequent filing plans.
  • The full credit facility is now accessible, which is relevant to assessing the company's ability to fund its late-stage programmes.
  • VP-315 in Gorlin syndrome is at an exploratory stage, so there is nothing yet to act on from a regulatory standpoint.

Company's press release (SEC filing): Verrica Pharmaceuticals Inc. ↗

Article written by VigiEye from the official source (Verrica Pharmaceuticals Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →